



Earnings Presentation – 4th Quarter, 2022

February 15, 2023

Disclaimer Statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this presentation other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions, are forward looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company’s expected results to differ materially from those expressed in this presentation. These factors include, among other things: general economic and business conditions, both nationally and in the regions in which we operate, including the current negative macroeconomic conditions, ongoing inflationary pressures that have significantly increased and may continue to significantly increase our expenses, the current high interest rate environment, ongoing challenging labor market conditions and labor shortages, and supply chain shortages and disruptions, as well as the current and/or potential future adverse impact of such economic conditions and other factors on our net operating revenues (including our service mix, revenue mix, payor mix and/or patient volumes) and our ability to collect outstanding receivables; developments related to COVID-19, including, without limitation, related to the length and severity of the pandemic; the volume of canceled or rescheduled procedures; and the spread of potentially more contagious and/or virulent forms of the virus, including variants of the virus for which currently available vaccines, treatments and tests may not be effective or authorized; uncertainty regarding the magnitude and timing of any future payments or benefits we may receive or realize under the Coronavirus Aid, Relief and Economic Security Act, the Paycheck Protection Program and Health Care Enhancement Act, the Consolidated Appropriations Act, 2021, the American Rescue Plan Act of 2021 and any other future stimulus or relief measures related to COVID-19; the impact of current or future federal and state health reform initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Affordable Care Act”), and the potential for changes to the Affordable Care Act, its implementation or its interpretation (including through executive orders and court challenges); the extent to and manner in which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through legislation, regulation or otherwise; the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process; risks associated with our substantial indebtedness, leverage and debt service obligations, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness, and our ability to remain in compliance with debt covenants; demographic changes; changes in, or the failure to comply with, federal, state or local laws or governmental regulations affecting our business; potential adverse impact of known and unknown legal, regulatory and governmental proceedings and other loss contingencies, including governmental investigations and audits, and federal and state false claims act litigation; our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers; changes in, or the failure to comply with, contract terms with payors and changes in reimbursement policies or rates paid by federal or state healthcare programs or commercial payors; any security breaches, cyber-attacks, loss of data, other cybersecurity threats or incidents, and any actual or perceived failures to comply with legal requirements governing the privacy and security of health information or other regulated, sensitive or confidential information, or legal requirements regarding data privacy or data protection; and the impact of the security breach announced by us on February 13, 2023, including legal, reputational, and financial risks associated with this security breach, the results of our ongoing investigation of this security breach, any potential regulatory inquiries and/or litigation to which we may become subject in connection with this security breach, and the extent of remediation and other additional costs that may be incurred by us in connection with this security breach; any potential impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies; the effects related to the implementation of the sequestration spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and the potential for future deficit reduction legislation; increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles; the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing; the impact of competitive labor market conditions and the shortage of nurses, including in connection with our ability to hire and retain qualified nurses, physicians, other medical personnel and key management, and increased labor expenses as a result of such competitive labor market conditions, inflation and competition for such positions; any failure to obtain medical supplies or pharmaceuticals at favorable prices; liabilities and other claims asserted against us, including self-insured professional liability claims; competition; trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals or via telehealth; changes in medical or other technology; changes in U.S. GAAP; the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures; our ability to successfully make acquisitions or complete divestitures, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures; the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities; our ability to successfully integrate any acquired hospitals and/or outpatient facilities, or to recognize expected synergies from acquisitions; the impact of severe weather conditions and climate change, as well as the timing and amount of insurance recoveries in relation to severe weather events; our ability to obtain adequate levels of insurance, including cyber, general liability, professional liability, and directors and officers liability insurance; timeliness of reimbursement payments received under government programs; effects related to pandemics, epidemics, or outbreaks of infectious diseases, including the coronavirus causing the disease known as COVID-19; any failure to comply with our obligations under license or technology agreements; challenging economic conditions in non-urban communities in which we operate; the concentration of our revenue in a small number of states; our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives; any changes in or interpretations of income tax laws and regulations; and the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2022 and other filings filed with the SEC.

The consolidated operating results for the three months and year ended December 31, 2022, are not necessarily indicative of the results that may be experienced for any future periods. The Company cautions that the projections for calendar year 2023 set forth in this presentation are given as of the date hereof based on currently available information. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

The hospitals, operations, and businesses described in this document are owned and operated by distinct and indirect subsidiaries of Community Health Systems, Inc.

Community Health Systems

- Tim L. Hingtgen
Chief Executive Officer
- Kevin J. Hammons
President and CFO
- Lynn T. Simon
President, Clinical Operations and CMO

Earnings Presentation – 4th Quarter, 2022

Near-Term Priorities



Near-term priorities
designed to
positively position CHS
for long-term success

Income Summary

(Amounts in millions, except margin and Net Income (Loss) per Share)

	Three Months Ended December 31,			Year Ended December 31,		
	2022	2021	Change	2022	2021	Change
Net Operating Revenues	\$ 3,142	\$ 3,233	-2.8%	\$ 12,211	\$ 12,368	-1.3%
Adjusted EBITDA ⁽¹⁾	\$ 404	\$ 540	- 25.2%	\$ 1,466	\$ 1,969	-25.5%
Adjusted EBITDA Margin ⁽¹⁾	12.9%	16.7%	(380) BPS	12.0%	15.9%	(390) BPS
Net Income (Loss) per Share, Excluding Adjustments ⁽²⁾	\$ 1.50	\$ 1.15		\$ (1.38)	\$ 2.45	
Shares Outstanding (Weighted and Fully Diluted)	130	133		130	131	

(1) See the Unaudited Supplemental Information contained in this presentation for a definition of Adjusted EBITDA and a reconciliation of Adjusted EBITDA, as defined, to net income attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements for the three months and years ended December 31, 2022 and 2021 (slides 16 and 17).

(2) See reconciliation of diluted net income (loss) per share, excluding adjustments, on slide 6.

Note: Consolidated hospital count of 80 at 12/31/2022 versus 83 at 12/31/2021.

During 4Q22, approximately \$2M of pandemic relief funds were recognized compared to approximately \$46M in the prior year period.

Diluted EPS – Excluding Adjustments

	Three Months Ended December 31,		Year Ended December 31,	
	2022	2021	2022	2021
Net income, as reported	\$ 3.18	\$ 1.34	\$ 0.35	\$ 1.76
Adjustments:				
(Gain) loss from early extinguishment of debt	(1.18)	-	(1.60)	0.89
Impairment and (gain) loss on sale of businesses, net	0.10	-	0.42	0.15
Gain from CoreTrust transaction	(0.71)	-	(0.71)	-
Gain on sale of equity interests in Macon Healthcare, LLC	-	(0.08)	-	(0.24)
Expense from government and other legal matters and related costs	-	-	0.03	-
(Income) expense from the settlement of professional liability claims for which the third-party insurers' obligation to insure the Company for the underlying loss has been settled	-	(0.11)	-	(0.11)
Expense related to employee termination benefits and other restructuring charges	0.03	-	0.04	-
Change in estimate for professional claims liability related to divested locations	0.09	-	0.09	-
Net income (loss), excluding adjustments	\$ 1.50	\$ 1.15	\$ (1.38)	\$ 2.45

(Total per share amounts may not add due to rounding)

4Q 2022 Summary

	Sequential 4Q 2022 compared to 3Q 2022	4Q 2022 compared to 4Q 2021		YE 2022 compared to YE 2021	
	Same Store	Consolidated Same Store		Consolidated Same Store	
Net Operating Revenue	4.8%	-2.8%	-1.3%	-1.3%	-0.2%
Net Revenue per AA	4.4%		-8.7%		-5.0%
Admissions	2.3%	1.9%	4.4%	-1.7%	0.5%
Adjusted Admissions	0.4%	5.2%	8.2%	2.6%	5.0%
Surgeries	2.5%	0.8%	4.2%	2.3%	4.0%
ER Visits	3.6%	7.1%	8.7%	3.2%	4.9%

Non-Labor Expense





<i>(\$ in millions)</i>	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22	4Q22
Supplies	\$491	\$500	\$529	\$521	\$499	\$487	\$492	\$498
Other Non-Labor	<u>\$749</u>	<u>\$740</u>	<u>\$730</u>	<u>\$743</u>	<u>\$740</u>	<u>\$757</u>	<u>\$799</u>	<u>\$805</u>
Total Non-Labor	\$1,240	\$1,240	\$1,259	\$1,264	\$1,239	\$1,244	\$1,291	\$1,303

Over 8 quarters, CHS mitigated the following material expense increases:

- New hospital openings
- Additional access points
- Conversion of software licensing to software as a service
- Record-high inflation

Total non-labor expense continues to trend below inflation.

Payor Mix (Consolidated)



Key


- Managed Care & Other
- Medicaid
- Medicare Managed Care
- Medicare
- Self-Pay

- Payor mix as % of net revenue.
- Total consolidated uncompensated care as % of adjusted net revenue (net revenue before provision for uncollectible revenue + charity care + administrative self pay discount) was 27.7% for 4Q22 compared to 25.2% for 4Q21.

Cash Flow & Capital Expenditures

Cash Flows from Operations

Excluding Received and Repaid Medicare Accelerated Payments
(\$ in millions)




Reported Cash Flows from Operations are provided in the Form 8-K dated February 15, 2023.

Excludes Medicare advance payments received of \$1,158 million as well as \$77 million repaid in 2020 and \$1,081 million repaid in 2021.

Capital Expenditures

(\$ in millions)



	2019	2020	2021	2022
CapEx % of Net Revenue (includes Replacement Hospitals)	3.3%	3.7%	3.8%	3.4%
Replacement Hospitals % of Net Revenue	0.4%	1.0%	0.5%	0.1%
Number of Hospitals at Year End	102	89	83	80


Balance Sheet Data

(\$ in millions)

	December 31, 2022	December 31, 2021
Working Capital	\$ 896	\$ 1,115
Total Assets	\$ 14,668	\$ 15,217
Total Debt	\$ 11,635	\$ 12,140
Stockholders' Deficit	\$ (1,367)	\$ (1,372)

- At December 31, 2022, substantially all of our debt was fixed rate debt.
- Days revenue outstanding for same-store hospitals, adjusted for the impact of receivables for state Medicaid supplemental payment programs, was 56 days at December 31, 2022 and 55 days at December 31, 2021.

Debt Maturity Profile



Note: Debt maturity profile does not include \$1 billion ABL Facility

Through capital market transactions in 2022, the Company extended \$1.5B of debt maturities and repurchased ~\$645M of debt with ~\$345M of cash, which lowered annual cash interest by ~\$58M.

2023 Guidance Issued February 15, 2023

	2023 Projection Range
• Net operating revenues (in millions)	\$12,200 to \$12,600
• Adjusted EBITDA (in millions)	\$1,475 to \$1,625
• Depreciation and amortization as a percentage of net operating revenues	4.2%
• Net loss per share – diluted	\$(0.65) to \$(0.05)
• Weighted-average diluted share (in millions)	130 to 131
• Net cash provided by operating activities (in millions)	\$675 to \$825
• Capital expenditures (in millions)	\$450 to \$500

Our comprehensive 2023 guidance has been provided on pages 17 and 18 on Form 8-K dated February 15, 2023 and includes important assumptions and exclusions.

The 2023 guidance excludes potential recognition of additional pandemic relief funds.

Medium-Term Financial Goals

	Medium-Term Within 3-5 Years
Net Revenue Growth	Mid-Single Digit
Adjusted EBITDA Margin	Mid-Teens
Annual Free Cash Flow	Positive
Financial Leverage (Net Debt / EBITDA)	Below 5.5x

Financial and operational goals focused on improving EBITDA margin and free cash flow as well as reducing financial leverage.

APPENDIX: Other Financial Information

Unaudited Supplemental Information

EBITDA is a non-GAAP financial measure which consists of net income attributable to Community Health Systems, Inc. before interest, income taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of equity interests in Macon Healthcare, LLC, expense related to government and other legal matters and related costs, expense incurred in the fourth quarter of 2020 related to the settlement of certain professional liability claims for which the third-party insurers' obligation to insure the Company against the underlying loss was being litigated along with income during the fourth quarter of 2021 associated with the settlement of such litigation for the recovery of amounts covered by such third-party insurance policies, expense related to employee termination benefits and other restructuring charges, the impact of a change in estimate to increase the professional liability claims accrual recorded during the fourth quarter of 2022 with respect to claims incurred in prior years related to divested locations, the gain on sale by HealthTrust of a majority interest in CoreTrust and expense from settlement and fair value adjustments on the contingent value right agreement liability related to the HMA legal proceedings and related legal expenses. The Company has included adjustments to Adjusted EBITDA during the fourth quarter of 2022 in relation to the impact of the change in estimate to increase the professional liability claims accrual with respect to claims incurred in prior years related to divested locations and the gain on sale by HealthTrust of a majority interest in CoreTrust, as noted above, in light of the fact that the Company believes that the exclusion of these items is consistent with the intended purpose of Adjusted EBITDA in assessing the Company's operational performance and comparing the Company's operational performance between periods. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company's hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company's executive management team and is one of the primary metrics used in connection with determining short-term cash incentive compensation and the achievement of vesting criteria with respect to performance-based equity awards. In addition, management utilizes Adjusted EBITDA in assessing the Company's consolidated results of operations and operational performance and in comparing the Company's results of operations between periods. The Company believes it is useful to provide investors and other users of the Company's financial statements this performance measure to align with how management assesses the Company's results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company's asset-based loan facility (the "ABL Facility") and the Company's existing note indentures, which is a key component in the determination of the Company's compliance with certain covenants under the ABL Facility and such note indentures (including the Company's ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the ABL Facility (although Adjusted EBITDA does not include all of the adjustments described in the ABL Facility). Adjusted EBITDA includes the Adjusted EBITDA attributable to hospitals that were divested during the course of such year, but in each case solely to the extent relating to the period prior to the consummation of the applicable divestiture.

Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures disclosed by other companies.

Unaudited Supplemental Information

The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net income attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements (in millions):

	Three Months Ended December 31,		Year Ended December 31,	
	2022	2021	2022	2021
Net income attributable to Community Health Systems, Inc. stockholders	\$ 414	\$ 178	\$ 46	\$ 230
Adjustments:				
(Benefit from) provision for income taxes	(121)	(2)	170	131
Depreciation and amortization	136	131	534	540
Net income attributable to noncontrolling interests	32	45	133	138
Interest expense, net	205	220	858	885
(Gain) loss from early extinguishment of debt	(180)	-	(253)	79
Impairment and (gain) loss on sale of businesses, net	17	-	71	24
Expense from government and other legal matters and related costs	-	-	5	-
(Income) expense from the settlement of professional liability claims for which the third-party insurers' obligation to insure the Company for the underlying loss has been settled	-	(19)	-	(19)
Expense related to employee termination benefits and other restructuring charges	5	-	6	-
Gain from CoreTrust transaction	(119)	-	(119)	-
Gain on sale of equity interests in Macon Healthcare, LLC	-	(13)	-	(39)
Change in estimate for professional claims liability related to divested locations	15	-	15	-
Adjusted EBITDA	\$ 404	\$ 540	\$ 1,466	\$ 1,969

Note: During the fourth quarter of 2022, pandemic relief funds of approximately \$2 million were recognized compared to approximately \$46 million in the fourth quarter of 2021. During 2022, pandemic relief funds of approximately \$173 million were recognized compared to approximately \$148 million in 2021.